With the deepening of medical reform, "instrument+reagent" The bundled sales model is about to exit the historical stage. The change in this policy means IVD Traditional business models in the industry will be impacted, For many IVD For manufacturers, This is not just a market strategy adjustment, It is also a test of one's own product line and service system. domestic IVD Enterprises will gain greater market space. Especially as importers gradually withdraw from the Chinese market, Local enterprises are expected to occupy a larger market share, Due to no longer being restricted by proprietary reagents of foreign brand instruments, domestic IVD Enterprises can rely on products and services with higher cost-effectiveness, Showcasing technological and innovative capabilities, Win the favor of more customers.

at the same time, Under the influence of the centralized procurement policy, Price competition will become more intense, How to ensure product quality while controlling prices, Becoming a presence IVD A major challenge facing enterprises, It forces companies to re-examine their business models, Searching for new profit points, The transition to digitization is imperative.

Analysis of the Competitive Landscape in the Intelligent Market

Market share expansion: with "reagent+instrument" The end of bundled sales model, Some imported brands may reduce or withdraw from the Chinese market due to the loss of their original market advantages, This is local IVD The enterprise provides an opportunity to expand its market share. Local enterprises can rely on products and services with higher cost-effectiveness, Win the favor of more customers.

Technological innovation drives development: The change in policies has forced enterprises to pay more attention to technological innovation and service optimization. If using artificial intelligence, Big data analysis and other methods, Digitize and intelligentize the production process. This can not only improve production efficiency, It can also enable enterprises to better understand market demand, Develop a reasonable business strategy, Thus gaining an advantage in the fierce market competition, Enable enterprises to maintain competitiveness while, Being able to provide higher quality products and services.

two, IVD The challenges faced by enterprises

*price issue: With the end of bundled sales model, Price wars will inevitably become one of the main ways of market competition. In order to compete for market share, IVD Manufacturers may need to lower reagent prices, Reduce costs by optimizing production and supply chain management, Ensure price competitiveness in fierce market competition, This will directly compress the profit margin. Moreover, Hospitals and clinics as the main purchasers, They will also have more bargaining chips, Further squeezing the profitability level of enterprises.

*Quality pressure: Outside of the price war, Enterprises also need to enhance their competitiveness by improving product quality and service levels. Customers will pay more attention to product performance and service support, Rather than a simple price factor. Therefore, Enterprises need to control costs while, Ensure that the product can have better quality.

*Changes in market landscape: Policy adjustments may lead to changes in market patterns. Some imported brands may gradually withdraw from the Chinese market due to losing the advantage of bundled sales, This provides more market opportunities for local enterprises. but at the same time, This also means that local enterprises need to face competition from other emerging market participants.

*Technology and Service Competition: Beyond the price, Technology and service quality will become the new focus of competition. Enterprises need to increase research and development investment, Launch more competitive products, Simultaneously optimize the after-sales service system, To enhance customer loyalty.

Thus it can be seen, How to control costs while, Ensure the reliability of products and service quality, Realize digital transformation, become IVD Key issues that enterprises urgently need to address.

The significance and value cognition of digital transformation

 Senxu Medical is based on AI Real time quality control intelligent monitoring platform for patient data (AI-PBRTQC) , Modeling based on international quality control management theory and authoritative statistical methods of national industry standards, It is the first independent product launched domestically, Original independent research and development using artificial intelligence and big data mining technology PBRTQC Professional intelligent quality control software tool, Highly praised by international experts for leading the international level.

so far, total100 Multiple hospitals participated in the China based project led by Senxu Medical AI of PBRTQC Real world big data performance validation and clinical application multi center demonstration project, Including large tertiary hospitals, Regional Inspection Center, private hospital, Community, etc, Senxu Medical AI-MA and AI-PBRTQC 2 A version of the product has been established75 Thousands of artificial intelligence models and billions of real-world big dataVerification and clinical application--The readiness and specificity for identifying quality risks and error results are as high as 98%above, At present, it should be the world's leading and largest in scale!

Senxu Medical AI-PBRTQC